Last edition
News about "obesity treatment "
Novo Nordisk Seeks FDA Approval for CagriSema Weight-Loss Therapy
CagriSema 2.4 mg/2.4 mg is an investigational once-weekly injectable combining cagrilintide and semaglutide to target complementary obesity pathways. In the REDEFINE 1 phase III trial, patients with obesity or overweight achieved an average weight loss of 23 percent, reinforcing the company’s ongoing focus on innovation in obesity treatment.
Obesity Treatment | 19/12/2025 | By News Bureau
Superluminal and Eli Lilly Partner on Next-Gen Cardiometabolic and Obesity Treatments
Superluminal Medicines has announced a collaboration with Eli Lilly and Company to advance small molecule therapeutics for cardiometabolic diseases and obesity.
Obesity Treatment | 16/08/2025 | By Dineshwori | 148
Novo Nordisk Partners with Fangzhou to Transform Diabetes and Obesity Management
Novo Nordisk and Fangzhou have signed a Memorandum of Understanding (MoU) to collaborate on the management of serious chronic conditions, including diabetes and obesity. <br />
Obesity Treatment | 22/07/2025 | By Dineshwori | 300
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy